Guardant Health, Inc. GH
154.78 USD -0.57 (-0.37%)
At closeNov 12, 2026, 8:30 AM EST
155.50 +0.72 +0.47%
Pre-market · Nov 12, 8:30 AM ET
153.41 Day range 163.39
74.55 52-week range 191.05
- YTD
- +51.54%
- 1 year
- +58.41%
News
businesswire.com Guardant Health Prices $500 Million Convertible Senior Notes Offering PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million…
businesswire.com Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million…
businesswire.com Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists…
businesswire.com PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective…
benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $193 to $190.
businesswire.com Guardant Health to Participate in Upcoming Investor Conferences PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor…
marketbeat.com What Guardant Health (GH) Said on Its Q3 Earnings Call Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based…
zacks.com Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.29 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.39 per share a year ago.
zacks.com Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
benzinga.com Guardant Health Q3 2026 Earnings Call Transcript Guardant Health (NASDAQ:GH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B Est Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.340 billion-$1.360 billion to $1.360 billion-$1.370 billion vs $1.357 billion estimate.
benzinga.com Guardant Health Q3 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $360.975M Beat $350.358M Estimate Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 25.64 percent increase over losses of…
businesswire.com Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third…
benzinga.com TwinStrand Biosciences Announces Confirmation Of U.S. Patent And Trademark Office Regarding Patentability Of All 23 Claims Of U.S. Patent Against Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing technology, today announced that the U.S. Patent and Trademark Office (USPTO) has confirmed the patentability of all 23 claims of…- benzinga.com BTIG Maintains Buy on Guardant Health, Raises Price Target to $210 BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
benzinga.com Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200 Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
benzinga.com TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected…- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.
- benzinga.com Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
benzinga.com Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220 Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.
benzinga.com S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
benzinga.com Guardant Health Announces Results From Its COSMOS-MEL01 Trial Shows 81% Sensitivity For Distant Recurrence, 100% Post-Treatment Facility Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published…- benzinga.com Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200 Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.
- benzinga.com Guardant Health’s Shield Blood Test For Colorectal Cancer Screening To Be Covered In EviCore By Evernorth Clinical Guidelines Effective January 1, 2027, Per ACS Guidelines Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersMilestone marks rapid…
- benzinga.com UBS Maintains Buy on Guardant Health, Raises Price Target to $225 UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
- benzinga.com Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203 Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.- benzinga.com Carelon Health Services To Cover Guardant Health’s Shield Blood Test Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield…
benzinga.com Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.- benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
- benzinga.com Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195 Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
benzinga.com Stifel Maintains Buy on Guardant Health, Raises Price Target to $180 Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.- benzinga.com RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200 RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
- benzinga.com Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200 Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
- benzinga.com JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195 JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $195.
- benzinga.com TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210 TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.
benzinga.com AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.
benzinga.com Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.- benzinga.com BTIG Maintains Buy on Guardant Health, Raises Price Target to $195 BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…- benzinga.com Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.
- benzinga.com Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of…
- benzinga.com Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190 Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $160 to $190.
- benzinga.com Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205 Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $205.
- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $175.
- benzinga.com Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215 Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.
- benzinga.com Evercore ISI Group Maintains Outperform on Guardant Health, Raises Price Target to $200 Evercore ISI Group analyst Vijay Kumar maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $160 to $200.
- benzinga.com B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $190 B of A Securities analyst Michael Ryskin maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $190.